Update: Enhertu Showed 61.6% 1-Yr Progression-Free Survival Destiny-Breast12 Study -ESMO
AstraZeneca's Enhertu displayed significant effectiveness in patients with HER2-positive metastatic breast cancer and brain metastases, achieving a 61.6% progression-free survival rate at one…